| Name | Title | Contact Details |
|---|
Tarrytown Expocare Pharmacy is a specialized long-term care pharmacy dedicated to serving individuals with intellectual and developmental disabilities (IDD) and behavioral health needs. The company operates across 30 U.S. states with ten physical locations, providing institutional pharmacy services to group homes, foster families, and residential care facilities. Tarrytown Expocare focuses on efficiency and safety, offering innovative solutions like color-coded blister packs to simplify medication administration. The pharmacy provides a range of services, including medication management, clinical collaboration, compliance support, and ongoing training for caregivers and nurses. Their secure online portal allows for 24/7 access to manage prescriptions and care coordination. Tarrytown Expocare emphasizes person-centric care and regulatory compliance, aiming to improve outcomes for vulnerable populations through reliable medication delivery and collaborative pharmacy solutions.
Transforming medicine through cellular therapies that restore, regenerate, and repair tissues and organs
Kirin Pharma USA is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ITOCHU Chemicals America is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MEI Pharma (Nasdaq: MEIP) is a San Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. Our approach to building our pipeline is to license promising cancer agents and create value in programs through development and commercialization, or strategic partnerships, as appropriate. Our portfolio contains four clinical-stage drug candidates, including one candidate in an ongoing global registration trial and another candidate that is anticipated to advance into a registration trial this year. Our drug candidate pipeline includes: Pracinostat, an oral HDAC inhibitor that is in a Phase 3 pivotal study in combination with azacitidine for the treatment of acute myeloid leukemia. Pracinostat is also being evaluated in a clinical study in patients with myelodysplastic syndrome. Pracinostat is licensed to Helsinn Healthcare SA, a Swiss pharmaceutical corporation. ME-401, a selective oral inhibitor of phosphatidylinositol 3-kinase (“PI3K”) delta. ME-401 is anticipated to progress into a single-agent registration study in 2018 for the treatment of adults with relapsed or refractory follicular lymphoma. Voruciclib, an orally administered and selective cyclin-dependent kinase (“CDK”) inhibitor differentiated by its potent in vitro inhibition of CDK9 in addition to CDK6, 4 and 1. Initiation of a Phase I dose-escalation study in patients with relapsed and/or refractory B-cell malignancies after failure of prior standard therapies is scheduled to being in the second calendar quarter of 2018. ME-344, a novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate, has demonstrated evidence of single-agent activity against refractory solid tumors in a Phase I study. In preclinical studies, tumor cells treated with ME-344 resulted in a rapid loss of ATP and cancer cell death. It is currently being evaluated in an investigator-initiated study in combination with the VEGF inhibitor bevacizumab (marketed as Avastin®) in patients with HER2 negative breast cancer.